Comparative Pharmacology
Head-to-head clinical analysis: CEFADROXIL versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADROXIL versus RESPORAL.
CEFADROXIL vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefadroxil is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
1-2 g orally once daily or divided into two doses every 12 hours.
2 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life 1.1-1.5 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease (CrCl <10 mL/min).
Clinical Note
moderateCefadroxil + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefadroxil."
Clinical Note
moderateCefadroxil + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefadroxil."
Clinical Note
moderateWarfarin + Cefadroxil
"Warfarin may increase the anticoagulant activities of Cefadroxil."
Clinical Note
moderatePhenprocoumon + Cefadroxil
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal (<5%).
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefadroxil."